Yahoo
Paris - Delayed Quote EUR

Virbac SA (VIRP.PA)

347.00 +2.50 (+0.73%)
At close: October 30 at 5:35:14 PM GMT+1
Chart Range Bar
Loading chart for VIRP.PA
  • Previous Close 344.50
  • Open 346.00
  • Bid --
  • Ask --
  • Day's Range 344.00 - 351.00
  • 52 Week Range 297.00 - 389.50
  • Volume 5,011
  • Avg. Volume 5,175
  • Market Cap (intraday) 2.908B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) 18.68
  • EPS (TTM) 18.58
  • Earnings Date Sep 17, 2026
  • Forward Dividend & Yield 1.45 (0.42%)
  • Ex-Dividend Date Jul 2, 2026
  • 1y Target Est 410.75

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

corporate.virbac.com

6,442

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

VIRP.PA
2.51%
CAC 40 (^FCHI)
2.21%

1-Year Return

VIRP.PA
0.70%
CAC 40 (^FCHI)
2.30%

3-Year Return

VIRP.PA
29.68%
CAC 40 (^FCHI)
16.77%

5-Year Return

VIRP.PA
19.00%
CAC 40 (^FCHI)
16.68%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 384M
Earnings --
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
100M
200M
300M
0.0%

Analyst Insights

View More

Analyst Price Targets

360.00
410.75 Average
347.00 Current
440.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/19/2021
Analyst Kepler Cheuvreux
Rating Action Upgrade
Rating Buy
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.43%

  • Return on Assets (ttm)

    7.60%

  • Return on Equity (ttm)

    13.62%

  • Revenue (ttm)

    1.49B

  • Net Income Avi to Common (ttm)

    155.85M

  • Diluted EPS (ttm)

    18.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    172.53M

  • Total Debt/Equity (mrq)

    29.71%

  • Levered Free Cash Flow (ttm)

    139.04M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: